Related Experiment Video
Updated: Jan 18, 2026
A Method to Define the Effects of Environmental Enrichment on Colon Microbiome Biodiversity in a Mouse Colon Tumor Model
Published on: February 28, 2018
Chemotherapy modulation by a cancer-associated microbiota metabolite
Daniel Martinez-Martinez1, Tanara V Peres1, Kristin Gehling2
1MRC Laboratory of Medical Sciences (LMS), Du Cane Road, London W12 0HS, UK; Institute of Clinical Sciences, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0HS, UK.
Abstract:
Understanding how the microbiota produces regulatory metabolites is of significance for cancer and cancer therapy. Using a host-microbe-drug-nutrient 4-way screening approach, we evaluated the role of nutrition at the molecular level in the context of 5-fluorouracil toxicity. Notably, our screens identified the metabolite 2-methylisocitrate, which was found to be produced and enriched in human tumor-associated microbiota. 2-methylisocitrate exhibits anti-proliferative properties across genetically and tissue-diverse cancer cell lines, three-dimensional (3D) spheroids, and an in vivo Drosophila gut tumor model, where it reduced tumor dissemination and increased survival. Chemical landscape interaction screens identified drug-metabolite signatures and highlighted the synergy between 5-fluorouracil and 2-methylisocitrate. Multi-omic analyses revealed that 2-methylisocitrate acts via multiple cellular pathways linking metabolism and DNA damage to regulate chemotherapy. Finally, we converted 2-methylisocitrate into its trimethyl ester, thereby enhancing its potency. This work highlights the great impact of microbiome-derived metabolites on tumor proliferation and their potential as promising co-adjuvants for cancer treatment.
Insights
Microbiome-produced 2-methylisocitrate inhibits cancer cell proliferation and enhances chemotherapy efficacy. This metabolite shows potential as a co-adjuvant for cancer therapy, improving treatment outcomes.
Area of Science:
- Microbiology
- Metabolomics
- Cancer Biology
- Pharmacology
Background:
- Microbiota-derived metabolites play a crucial role in cancer development and treatment.
- Understanding the molecular mechanisms of host-microbe interactions is vital for advancing cancer therapy.
Purpose of the Study:
- To investigate the role of nutrition and microbial metabolites in the context of 5-fluorouracil (5-FU) chemotherapy.
- To identify and characterize novel microbial metabolites with anti-cancer properties.
Main Methods:
- A 4-way screening approach (host-microbe-drug-nutrient) was employed.
- In vitro assays using cancer cell lines and 3D spheroids, and in vivo studies using a Drosophila gut tumor model.
- Chemical landscape interaction screens and multi-omic analyses were performed.
Main Results:
- The metabolite 2-methylisocitrate was identified as being produced by tumor-associated microbiota.
- 2-methylisocitrate demonstrated anti-proliferative effects across diverse cancer models and improved survival in vivo.
- Synergy was observed between 2-methylisocitrate and 5-fluorouracil, with the metabolite modulating chemotherapy response through metabolic and DNA damage pathways.
- A trimethyl ester derivative of 2-methylisocitrate showed enhanced potency.
Conclusions:
- Microbiome-derived 2-methylisocitrate possesses significant anti-tumor properties.
- 2-methylisocitrate acts as a regulator of chemotherapy, linking metabolism and DNA damage.
- This metabolite holds promise as a co-adjuvant for enhancing cancer treatment efficacy.
More Related Videos
06:07Evaluating Cell Death Using Cell-Free Supernatant of Probiotics in Three-Dimensional Spheroid Cultures of Colorectal Cancer Cells
Published on: June 13, 2020
07:15An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
Published on: July 31, 2019
Related Concept Videos
02:17The Tumor Microenvironment
01:15Drugs that Stabilize Microtubules
01:10Drugs that Destabilize Microtubules
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy